Seven Fleet Capital Management LP
13F Reported Value
ⓘ$605.9M
Holdings
96
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Seven Fleet Capital Management LP disclosed 96 positions worth $605.9M in its Form 13F-HR for Q2 2026, led by $CGON (CG Oncology, Inc.) at 22.1% of the equity portfolio, followed by $TNGX and $RVMD. During the quarter the fund opened 23 new positions and exited 41 — including a new stake in $MIRM. The portfolio is most concentrated in Healthcare (99.8% of disclosed assets). All figures are sourced directly from Seven Fleet Capital Management LP’s Form 13F-HR filing with the SEC under CIK 2092021.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 27.0#2,595
Quality
$134.0M1,886,236 sh - 17.6#2,824
Quality
$95.7M3,228,144 sh - —
Quality
$45.3M242,029 sh - —
Quality
$26.8M774,501 sh - 78.3
Quality
$20.5M256,603 sh - —
Quality
$18.5M365,386 sh - —
Quality
$14.8M111,334 sh - 11.7
Quality
$14.2M770,765 sh - 35.0
Quality
$12.9M110,393 sh - 41.5
Quality
$11.9M433,147 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 CG Oncology, Inc.$CGON | 27.0#2,595 | $134.0M | 1,886,236 |
 Tango Therapeutics, Inc.$TNGX | 17.6#2,824 | $95.7M | 3,228,144 |
 Revolution Medicines, Inc.$RVMD | — | $45.3M | 242,029 |
 Pharvaris N.V.$PHVS | — | $26.8M | 774,501 |
 Liquidia Corp$LQDA | 78.3 | $20.5M | 256,603 |
 Enliven Therapeutics, Inc.$ELVN | — | $18.5M | 365,386 |
 Abivax S.A.$ABVX | — | $14.8M | 111,334 |
 Avalo Therapeutics, Inc.$AVTX | 11.7 | $14.2M | 770,765 |
 Mirum Pharmaceuticals, Inc.$MIRM | 35.0 | $12.9M | 110,393 |
 ASSEMBLY BIOSCIENCES, INC.$ASMB | 41.5 | $11.9M | 433,147 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Seven Fleet Capital Management LP's 96 positions.
Showing top 10 of 96 holdings.
Sector Allocation
Healthcare
$604.8M
Other
$1.1M
Full Holdings — Seven Fleet Capital Management LP (Q2 2026)
All 96 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $CGON | CG Oncology, Inc. | $134.0M | 22.1% | +2390% | 27 |
| 2 | $TNGX | Tango Therapeutics, Inc. | $95.7M | 15.8% | +543% | 17.6 |
| 3 | $RVMD | Revolution Medicines, Inc. | $45.3M | 7.5% | +200% | — |
| 4 | $PHVS | Pharvaris N.V. | $26.8M | 4.4% | +348% | — |
| 5 | $LQDA | Liquidia Corp | $20.5M | 3.4% | +37% | 78.3 |
| 6 | $ELVN | Enliven Therapeutics, Inc. | $18.5M | 3.1% | +123% | — |
| 7 | $ABVX | Abivax S.A. | $14.8M | 2.5% | +159% | — |
| 8 | $AVTX | Avalo Therapeutics, Inc. | $14.2M | 2.4% | +260% | 11.7 |
| 9 | $MIRM | Mirum Pharmaceuticals, Inc. | $12.9M | 2.1% | NEW | 35 |
| 10 | $ASMB | ASSEMBLY BIOSCIENCES, INC. | $11.9M | 2.0% | +671% | 41.5 |
| 11 |  $IPSC | Century Therapeutics, Inc. | $10.7M | 1.8% | +47% | 33.5 |
| 12 |  $CYTK | CYTOKINETICS INC | $10.1M | 1.7% | +93% | 28.1 |
| 13 |  $TSHA | Taysha Gene Therapies, Inc. | $9.9M | 1.6% | +140% | 4.9 |
| 14 |  $MANE | Veradermics, Inc | $9.8M | 1.6% | NEW | — |
| 15 |  $AVBP | ArriVent BioPharma, Inc. | $8.6M | 1.4% | +391% | — |
| 16 |  $TARS | Tarsus Pharmaceuticals, Inc. | $7.9M | 1.3% | +491% | 55 |
| 17 |  $XNCR | Xencor Inc | $7.8M | 1.3% | +360% | 11.6 |
| 18 |  $ROIV | Roivant Sciences Ltd. | $7.8M | 1.3% | +72% | — |
| 19 |  $DMRA | Damora Therapeutics, Inc. | $7.4M | 1.2% | +181% | — |
| 20 |  $AXSM | Axsome Therapeutics, Inc. | $7.1M | 1.2% | +105% | 40.8 |
| 21 |  $DFTX | Definium Therapeutics, Inc. | $7.0M | 1.1% | +49% | — |
| 22 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $6.3M | 1.0% | +19% | 22.6 |
| 23 |  $COGT | Cogent Biosciences, Inc. | $5.7M | 0.9% | -1% | — |
| 24 |  $ERAS | Erasca, Inc. | $5.6M | 0.9% | +38% | — |
| 25 |  $PTGX | Protagonist Therapeutics, Inc | $5.6M | 0.9% | +1035% | 59.4 |
| 26 |  $NERV | Minerva Neurosciences, Inc. | $5.6M | 0.9% | +303% | — |
| 27 |  $EDIT | Editas Medicine, Inc. | $4.3M | 0.7% | NEW | 33.4 |
| 28 |  $CTMX | CytomX Therapeutics, Inc. | $4.1M | 0.7% | +192% | 8.7 |
| 29 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $4.0M | 0.7% | +41% | — |
| 30 |  $STRO | SUTRO BIOPHARMA, INC. | $3.8M | 0.6% | NEW | 15.3 |
| 31 |  $RLAY | Relay Therapeutics, Inc. | $3.3M | 0.6% | -31% | 19.5 |
| 32 |  $CLDX | Celldex Therapeutics, Inc. | $3.2M | 0.5% | +196% | 8.4 |
| 33 |  $ASND | Ascendis Pharma A/S | $3.2M | 0.5% | -3% | 44.8 |
| 34 |  $SGMT | Sagimet Biosciences Inc. | $3.1M | 0.5% | NEW | — |
| 35 |  $ZLAB | Zai Lab Ltd | $2.9M | 0.5% | +75% | — |
| 36 |  $SABS | SAB Biotherapeutics, Inc. | $2.9M | 0.5% | +636% | — |
| 37 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $2.7M | 0.4% | +47% | 40.7 |
| 38 |  $PRAX | Praxis Precision Medicines, Inc. | $2.5M | 0.4% | NEW | — |
| 39 |  $RLMD | RELMADA THERAPEUTICS, INC. | $2.4M | 0.4% | NEW | — |
| 40 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $2.1M | 0.3% | -73% | 26.9 |
| 41 |  $XENE | Xenon Pharmaceuticals Inc. | $2.1M | 0.3% | NEW | 24 |
| 42 |  $SVRA | Savara Inc | $1.9M | 0.3% | +5% | — |
| 43 |  $CCCC | C4 Therapeutics, Inc. | $1.8M | 0.3% | +568% | 18.2 |
| 44 |  $PCVX | Vaxcyte, Inc. | $1.8M | 0.3% | -73% | — |
| 45 |  $CELC | Celcuity Inc. | $1.7M | 0.3% | +171% | — |
| 46 |  $SNDX | Syndax Pharmaceuticals Inc | $1.6M | 0.3% | NEW | 33.8 |
| 47 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $1.5M | 0.2% | +189% | 11.6 |
| 48 |  $GPCR | Structure Therapeutics Inc. | $1.4M | 0.2% | +198% | — |
| 49 |  $LONA | LeonaBio, Inc. | $1.4M | 0.2% | -6% | — |
| 50 |  $IDYA | IDEAYA Biosciences, Inc. | $1.4M | 0.2% | -56% | 36.1 |
| 51 |  $GERN | GERON CORP | $1.4M | 0.2% | +149% | — |
| 52 |  $ANL | Adlai Nortye Group Ltd. | $1.3M | 0.2% | NEW | — |
| 53 |  $CRVS | Corvus Pharmaceuticals, Inc. | $1.2M | 0.2% | +0% | — |
| 54 |  $ALKS | Alkermes plc. | $1.2M | 0.2% | -4% | — |
| 55 |  $SYRE | Spyre Therapeutics, Inc. | $1.2M | 0.2% | -32% | — |
| 56 |  $CATX | Perspective Therapeutics, Inc. | $1.1M | 0.2% | -12% | — |
| 57 |  $OKUR | OnKure Therapeutics, Inc. | $1.1M | 0.2% | NEW | — |
| 58 |  $SMMT | Summit Therapeutics Inc. | $1.1M | 0.2% | NEW | — |
| 59 |  $ANTX | AN2 Therapeutics, Inc. | $1.0M | 0.2% | +5% | — |
| 60 |  $CTNM | Contineum Therapeutics, Inc. | $992,267 | 0.2% | +124% | — |
| 61 |  $TRVI | Trevi Therapeutics, Inc. | $833,430 | 0.1% | +68% | — |
| 62 |  $VYGR | Voyager Therapeutics, Inc. | $771,860 | 0.1% | +100% | 8.1 |
| 63 |  $IVA | Inventiva S.A. | $756,533 | 0.1% | +0% | — |
| 64 |  $ENGN | enGene Therapeutics Inc. | $711,142 | 0.1% | NEW | — |
| 65 |  $LRMR | Larimar Therapeutics, Inc. | $704,309 | 0.1% | -10% | — |
| 66 |  $IKT | Inhibikase Therapeutics, Inc. | $704,207 | 0.1% | +7% | — |
| 67 |  $NGNE | Neurogene Inc. | $693,787 | 0.1% | NEW | 27.4 |
| 68 | — | ISHARES TR - U.S. MED DVC ETF | $681,858 | 0.1% | NEW | — |
| 69 |  $SLN | Silence Therapeutics plc | $659,975 | 0.1% | -62% | — |
| 70 |  $KRYS | Krystal Biotech, Inc. | $659,343 | 0.1% | -59% | 79.2 |
| 71 |  $IRD | Opus Genetics, Inc. | $588,293 | 0.1% | +7% | — |
| 72 |  $PALI | PALISADE BIO, INC. | $568,906 | 0.1% | +28% | — |
| 73 |  $EOLS | Evolus, Inc. | $541,716 | 0.1% | +0% | 39 |
| 74 |  $UNCY | Unicycive Therapeutics, Inc. | $521,136 | 0.1% | +86% | — |
| 75 |  $CMPX | Compass Therapeutics, Inc. | $510,415 | 0.1% | -55% | 28.1 |
| 76 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $510,240 | 0.1% | -50% | 53.2 |
| 77 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $448,929 | 0.1% | +0% | — |
| 78 | — | PROTHENA CORP PLC - SHS | $423,907 | 0.1% | +0% | — |
| 79 |  $GLUE | Monte Rosa Therapeutics, Inc. | $406,560 | 0.1% | -25% | 30.3 |
| 80 |  $OLMA | Olema Pharmaceuticals, Inc. | $393,765 | 0.1% | NEW | — |
| 81 |  $MIST | Milestone Pharmaceuticals Inc. | $362,112 | 0.1% | -19% | — |
| 82 |  $ENTX | Entera Bio Ltd. | $338,697 | 0.1% | -7% | — |
| 83 |  $CUE | Cue Biopharma, Inc. | $337,755 | 0.1% | NEW | 28.9 |
| 84 |  $MBX | MBX Biosciences, Inc. | $331,200 | 0.1% | NEW | — |
| 85 |  $BEAM | Beam Therapeutics Inc. | $302,153 | 0.1% | +0% | 34.2 |
| 86 |  $AZN | ASTRAZENECA PLC | $265,468 | 0.0% | NEW | — |
| 87 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $261,138 | 0.0% | -13% | 8.7 |
| 88 |  $STOK | Stoke Therapeutics, Inc. | $255,353 | 0.0% | NEW | 24.9 |
| 89 |  $VKTX | Viking Therapeutics, Inc. | $251,884 | 0.0% | NEW | — |
| 90 |  $LPCN | Lipocine Inc. | $201,836 | 0.0% | -37% | — |
| 91 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $201,032 | 0.0% | -75% | — |
| 92 |  $PMN | ProMIS Neurosciences Inc. | $139,496 | 0.0% | +0% | — |
| 93 |  $WVE | Wave Life Sciences, Inc. | $99,812 | 0.0% | NEW | 7.5 |
| 94 |  $PMVP | PMV Pharmaceuticals, Inc. | $71,782 | 0.0% | -16% | — |
| 95 |  $FULC | Fulcrum Therapeutics, Inc. | $66,206 | 0.0% | -53% | 32.9 |
| 96 |  $QURE | uniQure N.V. | $15,254 | 0.0% | NEW | — |
New Positions (23)
$MIRM Mirum Pharmaceuticals, Inc.$12.9M$MANE Veradermics, Inc$9.8M$EDIT Editas Medicine, Inc.$4.3M$STRO SUTRO BIOPHARMA, INC.$3.8M$SGMT Sagimet Biosciences Inc.$3.1M$PRAX Praxis Precision Medicines, Inc.$2.5M$RLMD RELMADA THERAPEUTICS, INC.$2.4M$XENE Xenon Pharmaceuticals Inc.$2.1M$SNDX Syndax Pharmaceuticals Inc$1.6M$ANL Adlai Nortye Group Ltd.$1.3M$OKUR OnKure Therapeutics, Inc.$1.1M$SMMT Summit Therapeutics Inc.$1.1M$ENGN enGene Therapeutics Inc.$711,142$NGNE Neurogene Inc.$693,787Exited Positions (41)
$TYRA Tyra Biosciences, Inc.
$SLNO SOLENO THERAPEUTICS INC
$KALV KalVista Pharmaceuticals, Inc.
$MLYS Mineralys Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Seven Fleet Capital Management LP including:
Track Seven Fleet Capital Management LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Seven Fleet Capital Management LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Seven Fleet Capital Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For Seven Fleet Capital Management LP (SEC CIK: 2092021), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Seven Fleet Capital Management LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.